Here is an excerpt from MSAA's article on the latest MS treatment news:
"On March 28, 2017, the United States Food and Drug Administration (FDA) announced the approval of Ocrevus™ (ocrelizumab) for the treatment of two types of multiple sclerosis (MS): relapsing forms of MS (RMS) and primary-progressive MS (PPMS). This is the first time that a medication has been approved for two types of MS, and the first time that any medication has been approved for PPMS.
As noted, the approval is for relapsing forms of MS (RMS), which are characterized by sudden flare-ups and remissions. RMS includes relapsing-remitting MS (RRMS) as well as secondary-progressive MS (SPMS) with relapses. The approval is also for primary-progressive MS (PPMS), which is a less-common form of the disease and is characterized by a steady accumulation of symptoms.
Ocrevus™ (ocrelizumab) is a humanized monoclonal antibody and is given via intravenous (IV) infusion every six months. It has been shown to reduce annualized relapse rates and reduce disability progression when compared to control groups taking either an approved disease-modifying therapy or a placebo."
For more on Ocrevus, you can read MSAA's full news article here:
- John, MSAA